Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: durvalumab, PD-L1 inhibitors, PD-1/PD-L1 blockade, cancer immunotherapy, treatment safety, immune-related adverse events, pneumonitis, melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, gastroesophageal cancer, hepatocellular carcinoma, pancreatic cancer, triple-negative breast cancer, tumor response
Open Access status: closed
OpenAlex ID: W2474401389
